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Abstract: 
Background: Many recent studies support the idea that osteopontin (OPN) can be used to predict the success of  pegylated 
interferon (PEG IFN) alpha-2b/ribavirin therapy in chronic HCV patients. 
Objective: Our aim was to investigate the role of  plasma OPN and its gene polymorphism at nt – 443 in response to PEG IFN 
in Saudi patients with chronic HCV. 
Methods: Blood was collected from 87 patients with chronic hepatitis C before treatment, then patients received PEG IFN α2b 
plus ribavirin combination therapy. Another 25 healthy subjects, matched for age and sex to patients, were enrolled as controls. 
Single nucleotide polymorphism (SNP) in OPN at nt – 443 and its blood level were analyzed. 
Results: The frequency of  patients who reached sustained virological response (SVR) was increased in patients with T/T at 
nt – 443 than in those with C/C or C/T.  Also the frequency of  T allele was increased in responders than in non-responders. 
However, this increase was not statistically significant. The blood level of  OPN was significantly increased in non-responders 
(Mean±SD=37.21±3.9) in comparison to responders (Mean±SD=33.22±4.1). 
Conclusion: Osteopontin blood level can be considered as a reliable predictor to PEG IFN α2b plus ribavirin therapy in chronic 
HCV Saudi Patients. 
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Introduction
Infection with hepatitis C virus (HCV) is a common 
global cause of  chronic liver disease, which is also true 
in Saudi Arabia. HCV prevalence in Saudi Arabia varies 
in different provinces. The highest of  which being the 
Western and Southern provinces1. HCV was responsible 
for 35.4% of  chronic liver disase among Saudis, 74.2% 
among Egyptians, 28.6% among Yemenis and 24% 
among Palestinians2. Patients with post-necrotic liver cir-
rhosis secondary to HCV are also liable to develop hepa-
tocellular carcinoma (HCC) with an annual rate of  1 to 
4%3,4,5. 
OPN was shown to be essential for initiation of  T helper 
1(Th1) immune response at the upstream of  IL-18 and 
IL-12 in a cytokine network. Th1 immune response is 
involved in the development of  inflammation in chron-
ic hepatitis C, and the hepatocytes infected with HCV 
are eradicated by Th1 response during IFN-based ther-
apies6. Single nucleotide polymorphisms (SNPs) are the 
most common form of  genetic variation that has been 
employed for the prediction of  both disease progression7 
and therapeutic response8. Also, SNP was reported to be 
associated with a virologic response to IFN-based ther-
apy9. 
The aim of  our study was to analyze OPN protein level 
in the blood of  chronic HCV patients under treatment 
with interferon (responders and non-responders) and 
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their value as pre-treatment predictor of  responsiveness 




The present study was an observational case-control study. 
One hundred individuals were included in this study and 
divided into two groups; 87 naive chronic HCV-infected 
Saudi patients and 25 healthy Saudi patients.  Patients vis-
ited out-patient clinics of  Hepatology Department, King 
Abdul-Aziz Hospital, Taif, Saudi Arabia, during the pe-
riod from September 2013 to December 2013 and were 
diagnosed as chronically infected HCV patients. The se-
lection and sampling of  patients was done before starting 
treatment with PEG-IFN, then patients received interfer-
on based therapy at a dose of  1.5mg/kg subcutaneously 
every week plus ribavirin at dose of  600–1200mg/day, 
according to the patient’s body weight, for 48 weeks. All 
patients and control gave written informed consent to 
participate in the study.
The control group enrolled in the study comprised of  
25 healthy volunteer subjects with no evidence of  any 
chronic medical condition who matched age and sex 
with patients. Patients that participated in the study ful-
filled the following inclusion criteria: age 18–54 years, 
elevated alanine transaminase (ALT) and aspartate trans-
aminase (AST); within 6 months prior to entry of  the 
study, positive HCV antibodies, detectable HCV-RNA, 
HCV genotype 4, liver biopsy showing histological evi-
dence of  chronic hepatitis without cirrhosis or fibrosis, 
and they were never previously treated with IFN. Patients 
that presented with liver cirrhosis or hepatocellular car-
cinoma, haemoglobin (<11 g/dl), total leucocytes count 
(<3000/mm3), neutrophil (<1500/mm3), platelets (<100 
000/mm3), the presence of  anti-nuclear antibodies (titre 
<1/160), hepatitis B surface antigen seropositivity or au-
to-immune hepatitis or co-infection with HIV, and the 
presence of  any chronic systemic illness were excluded 
from this study.
According to response to treatment, patients were classi-
fied into two groups: Responders (50 patients) in whom 
serum HCV-RNA was not detected for 6 months after 
the discontinuation of  IFN-based therapies, they were 
classified as patients with SVR; and non-responders (37 
patients) who received treatment for 6 months and failed 
to clear the virus as the viral load measurement was as-
sessed by real time PCR. Liver biopsies were evaluated 
by a single expert pathologist and scored using the Ishak 
system in separate reports for grading and staging. All the 
participants in the study were F-0 by Ishak’s score.
Methods
Venous blood samples were collected in ethylene diamine 
tetraacetic acid (EDTA) and centrifuge tubes. The part in 
the centrifuge tube was incubated at 37˚C for 15 minutes, 
then centrifuged at 3000 rpm for 10 minutes at room tem-
perature. Serum was separated and used for biochemical 
characterization of  HCV specific antibody titers by en-
zyme-linked immunosorbent assay and enzymatic evalua-
tion of  ALT, AST, bilirubin, albumin and complete blood 
picture. These tests were performed at weeks one, two, 
four and monthly thereafter during treatment to detect 
the development of  any adverse side effects to the drugs 
necessitating dose modification, temporary or permanent 
stoppage of  treatment. Markers of  Hepatitis virus: hep-
atitis B surface antigen, anti-HBc and anti-HCV were as-
sessed by routine methods using commercially available 
assays. 
Viral RNA was extracted using viral RNA extraction kit 
(Qiagen) and stored at - 80˚C. HCV-RNA titer was mea-
sured before and after treatment by real-time PCR by 
Quanstudio 3 real time PCR system provided by Ther-
moFisher scientific. Thyroid function tests (T3, T4 and 
thyroid stimulating hormone) were performed (using 
Immulite) to all patients before receiving the treatment. 
Auto-antibodies (anti-nuclear antibodies and anti-DNA) 
were performed using Immunoflurescence kits. 
Quantitative detection of  HCV-RNA: Before treat-
ment Quantitative detection of  HCV-RNA in serum was 
measured routinely at weeks 24 and 48 after treatment 
and graded into low, moderate and high levels. HCV-
RNA was quantitated in all patients’ serum using real 
time polymerase chain reaction (RT-PCR) (Stratagene, 
LaJolla, CA, USA). According to quantitative PCR value, 
we can determine the level of  viremia and the response 
to the treatment. Each patient received sub-cutaneous 
injection of  PEG-IFN-a2b, at 1.5 mg/kg body weight 
once a week, combined with daily oral administration of  
ribavirin at a dosage that was determined on the basis 
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of  the patient’s body weight (600mg for <60 kg, 800mg 
for 60–80 kg and 1000–1200mg for >80 kg). Successful 
treatment was ascertained on the basis of  SVR, defined as 
HCV RNA-negative 6 months after cessation of  therapy. 
Estimation of  serum osteopontin protein: Human 
OPN in serum was measured using enzyme-linked im-
munosorbent assay kit provided by RayBio (RayBiotech, 
Inc., NY, USA). 
Analysis of  SNP in the promoter region of  OPN at 
nt – 443: Genomic DNA was extracted from peripher-
al blood mononuclear using the QIAamp DNA minikit 
(Qiagen, USA) following the manufacturer’s instructions. 
SNP in the promoter region of  OPN, at nt – 443 was 
determined by direct sequencing of  DNA fragments am-
plified by PCR.
Extracted genomic DNA was amplified in a 50 ul solu-
tion (using both forward and reverse primers) with the 
oligonucleotide primers determined from the sequence 
of  the promoter region of  human OPN as follows: For-
ward 50-TGTCACTAGTGCCATTTGT-30 and reverse 
50-TGTACCTTGGTCGGCGTTTG-30 . The reaction 
mixture was kept at 94◦C for 3 minutes for the enzyme 
activation, followed by 35 amplification cycles. Each cycle 
consisted of  denaturation at 94◦C for 30 seconds, primer 
annealing at 55◦C for 30 seconds, and primer extension 
at 72◦C for 60 seconds. Then, the mixture was incubated 
at 72C for 7 minutes for final primer extension and the 
PCR products were checked by DNA agarose gel electro-
phoresis. The PCR amplification product was detected at 
630 bp. Direct sequencing was performed with the use of  
The Big Dye Terminator mix V 3.1 system and ABI 310 
sequencer (ABI, Lincoln Center Drive Foster City, USA). 
Statistical analysis of  data: Statistical package for social 
sciences (IBM-SPSS), version 19 IBMChicago, USA was 
used for statistical data analysis. Data expressed as mean, 
standard deviation (SD), number and percentage. Mean 
and standard deviation were used as descriptive value for 
quantitative data. Student t test was used to compare the 
means between two groups, and one-way analysis of  vari-
ance (ANOVA) test was used to compare means of  more 
than two groups. Number and percentages were used to 
describe qualitative data. Chi square was used to com-
pare percentages between cases and controls. For all these 
tests, the level of  significance (P-value) was considered 
significant if  <0.05.
Informed consent: Written informed consent was ob-
tained from each patient before participating in the study 
according to the research and ethical committee of  Taif  
university, Taif, Saudi Arabia.
Results
Demographic and clinical features of  subjects in-
cluded in the study: Among 87 patients, there were 52 
(59.8%) men and 37 (40.2%) women, aged 40.62 ± 8.56 
years (mean ± SD), with a range of  18 to 54 years in the 
twenty five subjects control there were 19 (51.35%) males 
and 18 (48.65%) females with an average age of  33.10 
± 8.16 (mean ± SD). All the patients were genotype 4a 
and were treated with PEG-IFN alfa 2-b with  a dose 
of  1.5 µg/kg weekly and ribavirin (600 – 1200 mg/day) 
for 48 weeks. All the included patients were compensated 
and had no evidence of  fibrosis as assessed by clinical, 
laboratory and imaging investigations. The patients were 
classified into two groups: responders who included 50 
patients and non-responders who included 37 patients. 
All biochemical tests were significantly higher in hepatitis 
C patients than control group while there was no signifi-
cant difference observed regarding age and sex (Table 1).
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According to the response to PEG-IFN-α 2b plus rib-
avirin combination therapy, patients were divided into 
responders (n = 50) and non-responders (n = 37). Pa-
tients were considered to be responders if  they showed 
clearance of  the virus revealed by negative HCV-RNA 
after six months of  PEG-IFN-α 2b plus ribavirin com-
bination therapy. Interestingly, before starting the PEG-
IFN-α 2b plus ribavirin combination therapy, responders 
and non-responders showed no significant difference as 
regards sex and age. There were 46 responders and 34 
non responders. Responders showed significantly lower 
levels of  ALT, AST, ALP, PT, AFP ( P < 0.05) and signifi-
cantly higher plasma ALB level (P = 0.01) than non-re-
sponders. The clinical background features of  responders 
and non-responders before starting therapy were shown 
in Table (2).




Variables Control (n=25) 
Mean ± SD 
Hepatitis C patients (n=87) 
Mean ± SD 












P=0.0001*  36±8.0 87.8±58.2 ALT (U/L) 
P=0.0001* 33.8±7.5 107±65.8 AST (U/L) 
P=0.0001* 0.83±0.3 1.43±0.79 Total Bilirubin (mg/dl) 
 P=0.0001* 0.19±0.08 0.46±0.28 Direct Bilirubin (mg/dl) 
P=0.0001* 48.7±8.6 123.5±53.4 Alkaline phosphatase  (U/L)  
 P=0.0001* 3.93±0.53 3.29±0.45 Albumin (g/l) 
P=0.0001* 4.7±1.8 14.2±8.3 Alfa fetoprotein (ng/ml) 
P=0.0001* 10.1±0.4 13.5±1.7 Prothrombin time (seconds) 
P=0.0001* 24.3±8.8 35.21±4.3 Osteopontin protein (ng/ml) 
             * Indicate a statistical significant difference 





Variables Non responders (n=37) 
Mean ± SD 
Responders (n=50) 
Mean ± SD 
0.24 42.5±9.8 41.4±9.4 Age 












P=0.000* 92.4±29.8 70.2±33.5 ALT (U/L) 
P=0.000* 88.3±37.6 62.7 ±28.9 AST (U/L) 
P=0.74  0.75±0.4 0.83±0.33 Total Bilirubin (mg/dl) 
P=0.58  0.22±0.24 0.24±0.21 Direct Bilirubin (mg/dl) 
P=0.02* 96.2±7.5 93.3±9.4 Alkaline phosphatase  (U/L)  
P=0.01* 3.63±0.27 3.47±0.31 Albumin (g/l) 
P=0.06  10.9±4.2 10.5±3.8 Alfa fetoprotein (ng/ml) 
P=0.004 * 13.8±1.9 13.3±2.6 Prothrombin time (seconds) 
P=0.0001* 37.82±4.8 34.75±6.4 Osteopontin protein (ng/ml) 
    
                           * Indicate a statistical significant difference 
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The genotypes and allele frequencies at the promoter re-
gion of  osteopontin gene at nt – 443 were significantly 
different between patients and controls and also between 
responders and non-responders. In patients who reached 
sustained virological response (SVR) the frequency of  
T/T genotype at nt – 443  was higher than C/C or C/T. 
Also, the frequency of  T allele was increased in respond-
ers than in non-responders. (Table 3)
Table 3: Prevalence of single nucleotide polymorphism (-443) in the promoter region of 
osteopontin gene and allelle frequency in patients and control 
 
 

















































































* The comparison was made between TT genotype against C/T+C/C assuming a dominant model  
Discussion
Hepatitis C virus belongs to the genus Hepacivirus, a mem-
ber of  the family Flaviviridae. Until recently it was consid-
ered to be the only member of  this genus10.  The majority 
of  HCV infected patients do not clear the virus and this 
leads to chronic hepatitis which may progresses to liver fi-
brosis, cirrhosis and hepatocellular carcinoma (HCC)4,5,11. 
The goal of  HCV treatment is to cure the virus, which 
can be done with a combination of  drugs. Although the 
treatment of  chronic HCV has now been revolutionized 
with new drugs, during the time period of  conducting the 
study the treatment protocol of  chronic HCV was PEG-
IFN in combination with ribavirin. Being expensive, in-
volving severe side effects and requiring long treatment 
duration, the therapy is creating a huge burden on the 
country. Predictive factors regarding treatment response 
are not well established for each individual and do not 
allow personalizing the treatment. Therefore, accurate 
prediction of  response to the therapeutic regimen is of  
great interest. So, finding genomic based predictors of  
pre-treatment response to anti-viral therapy is an essential 
issue12,13.
This current therapy is inefficient, mainly due to usually 
late diagnosis and high recurrence rate within the remain-
ing cirrhotic liver after surgical resection. It is a multistep 
process involving different genetic alterations that ulti-
mately lead to malignant transformation of  hepatocytes. 
HBV and HCV chronic infections account for 75% of  
HCCs, whereas non-viral etiologies such as alcohol and 
genetic or metabolic disorders represent less than 25% 
of  cases. HCV-induced chronic liver injury can lead to 
progressive fibrosis, cirrhosis and eventually HCC4,5,11,14. 
HCV-associated HCC has been reported to promote tu-
mor growth and metastasis due to an increased recurrence 
after liver resection. However, the underlying mechanisms 
responsible for metastatic spread of  HCV-induced HCC 
are not fully elucidated15.
Osteopontin (OPN) is a secreted phosphoprotein, orig-
inally characterized in malignant-transformed epithelial 
cells. OPN is associated with tumor metastasis of  several 
tumors and over-expressed in hepatocellular carcinoma 
(HCC)16. Importantly, OPN is significantly up-regulated 
in liver injury, inflammation and HCV- associated HCC. 
However, the underlying mechanisms of  OPN activation 
and its role in HCV-mediated liver disease pathogenesis 
are not known15. Previous studies have demonstrated that 
OPN is involved in tumor metastasis and has been de-
tected not only in numerous cancers but also in plasma 
of  HCV related HCC patients, suggesting a correlation 
between high levels of  OPN expression and malignant 
invasion16,17,18. 
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Osteopontin is shown to be essential for initiation of  Th1 
immune response at the upstream of  IL-18 and IL-12 in a 
cytokine network. The Th1 immune response is involved 
in the development of  inflammation in chronic hepatitis 
C, and the hepatocytes infected with HCV are eradicated 
by Th1 response during IFN-based therapies6.
In this study, we analyzed OPN blood levels in chronic 
HCV patients before treatment with interferon, according 
to their response to interferon they were either (respond-
ers or non-responders). and their value as a pretreatment 
predictor of  responsiveness to treatment. The present 
study was conducted on 87 patients with chronic hepa-
titis C who received PEG-¬IFN alpha-2b plus ribavirin. 
There were 52 men and 35 women, aged 40.62 ± 8.56 
years, with a range of  18 to 54 years. No significant differ-
ence was observed as regards to different genotype dis-
tribution between them. The results of  the current study 
revealed that, the sustained virological response (SVR) to 
PEG-IFN alpha-2b plus ribavirin therapy was 60 %. This 
is comparable with response rate (63%) predicted by Al 
Ashgar et al.,19 but is higher compared to that reported 
by kamal et al.,20 which was 48 %. And is lower compared 
to that reported by Al Ashgar et al.,21 which was (75.6%).
Results of  our study concluded that the allele frequencies 
but not genotypes at the promoter region of  osteopon-
tin gene at nt – 443 were significantly different between 
patients and controls. Frequency of  patients who reached 
sustained virological response (SVR) was increased in 
patients with T/T at nt – 443 than in those with C/C 
or C/T. Also the frequency of  T allele was increased in 
responders than in non responders. However, the geno-
types and allele distribution showed no statistically signif-
icant difference between responders and non responders.
In the present study, a clear relationship between baseline 
of  OPN protein level in blood of  chronic hepatitis C pa-
tients and response to treatment was observed.  Lower 
pre-treatment plasma OPN protein was correlated with 
better response. This finding is further verified by Huang 
et al.,22 study which found that OPN concentrations were 
significantly increased in the HCV individual with exten-
sive fibrosis and inflammation. They provide evidence 
that the surveillance of  plasma OPN concentration may 
be a non-invasive biomarker for the evaluation of  severity 
of  liver damage in HCV-infected subjects. Other previ-
ous results suggest that HCV infection induces OPN via 
altered Ca2+ homeostasis in the endoplasmic reticulum 
and elevation of  reactive oxygen species in the mitochon-
dria. Also, Ca2+ mediated mitochondrial dysfunction has 
been suggested to play an important role in HCV-me-
diated liver disease pathogenesis23. In other studies, they 
observed that the induction of  OPN is mediated by the 
activation of  cellular kinases24.
Also, Cheng and Mahato25 study showed that the OPN 
might be a central pathway of  HSC (hepatic satellite cell) 
activation. HSC is largely responsible for the develop-
ment of  liver inflammation and cirrhosis in the liver by 
increasing the ECM (extra cellular matrix) deposition in 
the sub-endothelial space between hepatocytes and endo-
thelial cells. Our results highlight the correlation between 
plasma OPN concentration in HCV-infected subjects and 
response to combination treatment (PEG -INF and riba-
virin) of  chronic hepatitis C patients.
Conclusion
The results of  this study proved that osteopontin level 
but not its SNP at nt – 443 is a good predictor of  re-
sponse to interferon based therapy in Saudi patients with 
chronic HCV infection.  
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